MarketPulse
financial resultsearnings guidancerare disease

ANI Pharmaceuticals to Report 2025 Results, Reaffirms Guidance Expectations

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

ANI Pharmaceuticals will report 2025 results on February 27, 2026, reaffirming confidence in meeting or exceeding guidance for revenues, EBITDA, and earnings per share.

ANI Pharmaceuticals to Report 2025 Results, Reaffirms Guidance Expectations
$ANIPpositive

ANI Pharmaceuticals has scheduled the release of its fourth quarter and full-year 2025 financial results for February 27, 2026, prior to market open. The company has signaled confidence in its annual performance, indicating that full-year revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted earnings per share are expected to meet or exceed previously established guidance ranges.

CEO Nikhil Lalwani and other company executives will host a conference call following the earnings release to discuss the financial results and address analyst questions. The call will provide stakeholders with insight into the company's operational performance and strategic positioning as it enters the new year.

Topics

financial resultsearnings guidancerare diseaseconference callbiopharmaceuticalfourth quarter 2025

Source: GlobeNewswire Inc.

Back to newsPublished Feb 13

Related Coverage

GlobeNewswire Inc.

Sika AG Shareholders Approve Board, Boost Dividend to CHF 3.70 Per Share

Sika AG shareholders approved CHF 3.70 dividend and board re-election at 2026 AGM, with company reporting CHF 11.20B sales and 33,700 employees globally.

SXYAY
GlobeNewswire Inc.

17EdTech Posts Narrower Loss Despite Revenue Decline as AI Product Gains Traction

17EdTech reports Q4 revenue growth of 6.4% YoY and significant margin expansion, though full-year revenues declined 44% due to business model shift. New AI product 'Yiqi Aixue' shows strong pre-sale demand.

YQ
The Motley Fool

Slide Insurance Posts $444M Profit on Strong Revenue Growth; Insider Trims Position

Slide Insurance reported $444M net income and $1.16B revenue, up 36% YoY. Director sold $1M in shares via pre-arranged plan while maintaining substantial stake.

SLDE
Benzinga

Baxter Cancer Drug Supply Crisis Compounds Earnings Weakness

Baxter faces EU cancer drug shortage extending to Q1 2027 amid disappointing 2026 earnings guidance, projecting $1.85-$2.05 EPS versus $2.25 consensus.

BAX
Benzinga

Alfa Laval Sets Q1 2026 Earnings Release; Conference Call Scheduled for April 22

Alfa Laval will release Q1 2026 earnings April 22, 2026, followed by investor conference call hosted by CEO Tom Erixon and CFO Fredrik Ekström.

ALFVY
GlobeNewswire Inc.

IMUNON Sets March 31 Call to Detail 2025 Results, OVATION 3 Trial Progress

$IMNN to discuss 2025 results and OVATION 3 Phase 3 trial progress for IMNN-001 ovarian cancer immunotherapy on March 31, 2026.

IMNN